Login to Your Account

Pharma: Other News To Note

Thursday, May 10, 2012
• Janssen Research & Development LLC, of Raritan, N.J., a subsidiary of Johnson & Johnson, submitted a supplemental new drug application to the FDA for the use of Xarelto (rivaroxaban), an oral anticoagulant, to reduce the risk of stent thrombosis in patients with acute coronary syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription